Hauv kev sib tw ntawm cov kws tshawb fawb tshuaj thiab kev loj hlob, ua kom nrawm thiab ua tau zoo txiav txim siab ua tiav lossis tsis ua tiav. Kev muab cov khoom siv hauv nruab nrab feem ntau ua ib qho kev txhim kho molecule kom tau raws li, kev siv zog ua tsis tau muaj peev xwm ua tau zoo, thiab muaj peev xwm ua tau ntev dua tuaj yeem sib txuam, thiab tsis muaj peev xwm ua tau cov khoom siv hluav taws xob zoo sib xws. Customized Synthesesesesis kev pabcuam, nrog lawv cov ntse dua - hloov hluavtaws yooj yim kom tawg los ntawm kev teeb meem tseem ceeb, thiab lawv tus nqi tau lees paub meej los ntawm cov ntaub ntawv tiag tiag.
Leading service providers usually reserve 15+ core chemical technology platforms (such as chiral synthesis, catalytic hydrogenation, continuous flow chemistry, and special heterocyclic construction). For new target molecules, 3-5 potential synthesis routes can be quickly screened and optimized. A customer developed a new antiparasitic azole derivative and needed a key fluoropiperidine intermediate. The service provider evaluated and locked the optimal path within 4 weeks (compared to the customer's internal estimate of 8-12 weeks), and the first batch of high-purity (>98.5%) Kuaj cov qauv tau xa mus rau 6 lub lis piam ua ntej lub sijhawm ua ntej ntawm cov neeg sib tw ntawm cov tshuaj sib tw (cov ntaub ntawv: Kev Ntsuam Xyuas Kev Lag Luam Kev Ntsuam Xyuas).
Professional custom synthesis platform can cover milligram-level to ton-level production. From preclinical toxicology batches (100g - 1kg) to Phase I-III clinical supply (10kg - 500kg/batch), and then to commercial preparation (>1 nyhav ib tuj / batch), linear los yog cov kauj ruam-nrog-qib kev txhawb nqa yog muab. Nrog kev hloov tau yooj yim "ntawm kev thov kev tsim khoom" qauv, cov qauv peev muaj peev xwm ua tau raws li kev sib piv Ib lub tuam txhab biotechnology tsom rau kev txhim kho cov tsiaj uas anti-inflammogy tau txo cov pipeline kev nqis peev los ntawm 35% siv tus qauv no.
Yooj taus yeej tsis yog kev coj ua ntawm qhov tsis zoo. Kev vam meej kev cai synthesis yog ua rau lub suab zoo (CGMP / GMP):
1. Cov ntaub ntawv Rigor: Batch tso tawm muab cov ntaub ntawv txheeb xyuas cov ntaub ntawv (HPLC / NMR, cov tshuaj uas hnyav, thiab lwm yam) kom ua tiav cov qauv nruj.
2. Cov ntaub ntawv txhawb nqa: Muab cov ntaub ntawv foos (cov ntaub ntawv siv tshuaj yeeb) lossis daim ntawv pov thawj ntawm cov chaw tso npe European) npaj kev pabcuam kom nrawm rau kev sau npe tshuaj.
The core value of customized veterinary intermediates lies in the flexible synthesis capability to cope with the uncertainty of drug development. Data clearly shows that it plays an irreplaceable role in accelerating the R&D cycle (shortening the time to obtain molecules by 30%-50%), reducing early costs (saving 40%+ initial investment), and overcoming complex chemical problems (achieving >99% EE thiab high-teeb meem synthesis).